A study to check reduction in blood glucose level over 24 hours after consuming anti-diabetic medicines- Lobeglitazone or Pioglitazone using Continuous Glucose Monitoring device.

A Prospective open-labelled three-armed pilot study to evaluate TIR parameters in T2DM patients on Lobeglitazone and Pioglitazone

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050577

Enrollment

Registered

2023-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Lobeglitazone: 0.5mg OD for 14 days Control Intervention1: Pioglitazone: 15 mg OD for 14 Days Control Intervention2: Pioglitazone: 30 mg OD for 14 Days

Eligibility

Inclusion criteria

Inclusion criteria: T2DM patient with HbA1c >=7% to <=8.5% and on metformin monotherapy

Exclusion criteria

Exclusion criteria: Patients taking any other anti-diabetic medication at screening other than metformin

Design outcomes

Primary

Measure	Time frame
evaluation of change in TIR from baseline to day 14Timepoint: 14 days	—

Secondary

Measure	Time frame
evaluation of change in TAR, TBR, MAGE and other CGM parametersTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr Suhas Gopal Erande

Akshay Hospital

drsse@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026